DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450)

South Korea flag South Korea · Delayed Price · Currency is KRW
17,800
+200 (1.14%)
Aug 14, 2025, 2:40 PM KST
4.95%
Market Cap 781.30B
Revenue (ttm) 839.08B
Net Income (ttm) 57.60B
Shares Out 44.39M
EPS (ttm) 1,296.85
PE Ratio 13.57
Forward PE 10.56
Dividend 200.00 (1.14%)
Ex-Dividend Date Dec 27, 2024
Volume 128,676
Average Volume 180,899
Open 17,770
Previous Close 17,600
Day's Range 17,600 - 18,030
52-Week Range 14,400 - 19,150
Beta 0.31
RSI 45.26
Earnings Date Aug 14, 2025

About DongKook Pharmaceutical

DongKook Pharmaceutical Co., Ltd. produces and sell pharmaceutical products in South Korea and internationally. The company offers non-prescription and prescription drugs, quasi drugs, medical devices, active pharmaceutical ingredients, cosmetics, and other processed products. Its pipeline includes DKF-MB601, used to treat Hepatitis B; DKF-MB501, to treat obesity; DKM-412 and DKM-420 to treat osteoarthritis; DKF-313, indicated for benign prostatic hyperplasia; DKF-447, to treat diabetes; DKB-123, used for wound healing, tissue repair; and DKM-4... [Read more]

Sector Healthcare
Founded 1968
Employees 1,183
Stock Exchange KOSDAQ
Ticker Symbol 086450
Full Company Profile

Financial Performance

In 2024, DongKook Pharmaceutical's revenue was 812.17 billion, an increase of 11.10% compared to the previous year's 730.99 billion. Earnings were 60.77 billion, an increase of 29.92%.

Financial Statements

News

There is no news available yet.